HCC heterogeneity: Molecular pathogenesis and clinical implications

Cellular Oncology

Volumn 31, Issue 3, 2009, Pages 227-233

  Fransvea, Emilia ^a   Angelo, Paradiso ^b   Antonaci, Salvatore ^a   Giannelli, Gianluigi ^a,c  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c POLICLINICO   (Italy)

Author keywords

Biological therapies; HCC; Heterogeneity; Molecular pathogenesis; TGF 1; Tissue microenvironment; TK receptors; Tumor progression

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MATRIX METALLOPROTEINASE; PROTEIN TYROSINE KINASE; SEMAXANIB; SORAFENIB; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE KINASE RECEPTOR; VANDETANIB;

CANCER CELL; COLON CANCER; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LUNG CANCER; METASTASIS; MICROENVIRONMENT; NONHUMAN; ONCOGENE MYC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS;

EID: 67650260629     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.3233/CLO-2009-0473     Document Type: Review

References (55)

1. G.K. Abou-Alfa, L. Schwartz, S. Ricci, D. Amadori, A. San- toro, A. Figer, J. De Greve, J.Y. Douillard, C. Lathia, B. Schwartz, I. Taylor, M. Moscovici and L.B. Saltz, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma, J. Clin. Oncol. 24(2006), 4293-4300.
2. P. Bedossa, E. Peltier, B. Terris, D. Franco and T. Poynard, Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers, Hepatology 21(1995), 760-766.
3. C. Bergamini, C. Sgarra, P. Trerotoli, L. Lupo, A. Azzariti, S. Antonaci and G. Giannelli, Laminin-5 stimulates hepato- cellular carcinoma growth through a different function of al- pha6beta4 and alpha3beta1 integrins, Hepatology 46(2007), 1801-1809.
4. T. Brabletz, F. Hlubek, S. Spaderna, O. Schmalhofer, E. Hiendlmeyer, A. Jung and T. Kirchner, Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin, Cells Tissues Organs 179(2005), 56-65.
5. K. Breuhahn, T. Longerich and P. Schirmacher, Dysregulation of growth factor signaling in human hepatocellular carcinoma, Oncogene 25(2006), 3787-3800.
6. J. Bruix and M. Sherman, Management of hepatocellular carcinoma, Hepatology 42(2005), 1208-1236.
7. R.E. Burgeson, M. Chiquet, R. Deutzmann, P. Ekblom, J. En- gel, H. Kleinman, G.R. Martin, G. Meneguzzi, M. Paulsson and J. Sanes, A new nomenclature for the laminins, Matrix Biol. 14(1994), 209-211.
8. A. Cano, M.A. Perez-Moreno, I. Rodrigo, A. Locascio, M.J. Blanco, M.G. del Barrio, F. Portillo and M.A. Nieto, The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression, Nat. Cell Biol. 2(2000), 76-83.
9. M. Colombo, Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma, J. Hepatol. 31(Suppl. 1)(1999), 25-30.
10. E.C. Douglass, Development of ZD1839 in colorectal cancer, Semin. Oncol. 30(2003), 17-22.
11. N. Dumont and C.L. Arteaga, Targeting the TGF beta signaling network in human neoplasia, Cancer Cell 3(2003), 531-536.
12. E. Fransvea, A. Angelotti, S. Antonaci and G. Giannelli, Blocking transforming growth factor-beta (TGF-/3) up-regulates E-cadherin and reduces migration and invasion of HCC cells, Hepatology 5(2008), 1557-1566.
13. G. Giannelli, A. Azzariti, E. Fransvea, L. Porcelli, S. Antonaci and A. Paradiso, Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells, Br. J. Cancer 91(2004), 1964-1969.
14. G. Giannelli, A. Azzariti, C. Sgarra, L. Porcelli, S. Antonaci and A. Paradiso, ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells, Biochem. Pharmacol. 71(2006), 479-485.
15. G. Giannelli, C. Bergamini, E. Fransvea, C. Sgarra and S. An- tonaci, Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma, Gastroenterology 129(2005), 1375-1383.
16. G. Giannelli, C. Bergamini, F. Marinosci, E. Fransvea, M. Quaranta, L. Lupo, O. Schiraldi and S. Antonaci, Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma, Int. J. Cancer 97(2002), 425-431.
17. G. Giannelli, E. Fransvea, F. Marinosci, C. Bergamini, S. Colucci, O. Schiraldi and S. Antonaci, Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin, Am. J. Pathol. 161(2002), 183-193.
18. A. Haringhuizen, H. Van Tinteren, H.F. Vaessen, P. Baas and N. Van Zandwijk, Gefitinib as a last treatment option for non- small-cell lung cancer: durable disease control in a subset of patients, Ann. Oncol. 15(2004), 786-792.
19. R.S. Herbst, Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients, Semin. Oncol. 30(2003), 30-38.
20. A. Huether, M. Hopfner, A.P. Sutter, D. Schuppan and H. Scherubl, Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics, J. Hepatol. 43(2005), 661-669.
21. N. Iizuka, M. Oka, H. Yamada-Okabe, M. Nishida, Y. Maeda, N. Mori, T. Takao, T. Tamesa, A. Tangoku, H. Tabuchi, K. Hamada, H. Nakayama, H. Ishitsuka, T. Miyamoto, A. Hirabayashi, S. Uchimura and Y. Hamamoto, Oligonu- cleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection, Lancet 361(2003), 923-929.
22. W. Jiao, K. Miyazaki and Y. Kitajima, Inverse correlation between E-cadherin and Snail expression in hepatocellular carcinoma cell lines in vitroand in vivo, Br. J. Cancer 86(2002),98-101.
23. D.H. Johnson, L. Fehrenbacher, W.F. Novotny, R.S. Herbst, J.J. Nemunaitis, D.M. Jablons, C.J. Langer, R.F. DeVore III, J. Gaudreault, L.A. Damico, E. Holmgren and F. Kabbinavar, Randomized phase II trial comparing bevacizumab plus carbo- platin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small- cell lung cancer, J. Clin. Oncol. 22(2004), 2184-2191.
24. Y. Kurokawa, R. Matoba, I. Takemasa, H. Nagano, K. Dono, S. Nakamori, K. Umeshita, M. Sakon, N. Ueno, S. Oba, S. Ishii, K. Kato and M. Monden, Molecular-based prediction of early recurrence in hepatocellular carcinoma, J. Hepatol. 41(2004),284-291.
25. J.S. Lee, J. Heo, L. Libbrecht, I.S. Chu, P. Kaposi-Novak, D.F. Calvisi, A. Mikaelyan, L.R. Roberts, A.J. Demetris, Z. Sun, F. Nevens, T. Roskams and S.S. Thorgeirsson, A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells, Nat. Med. 12(2006), 410-416.
26. W.J. Lee, R.L. Hong, I.R. Lai, C.N. Chen, P.H. Lee and K.C. Chung, Reappraisal of the new UICC staging system for gastric cancer: problem in lymph node stage, Hepatogastroenterology 49(2002), 860-864.
27. L.A. Liotta and E.C. Kohn, The microenvironment of the tumour-host interface, Nature 411(2001), 375-379.
28. L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, D. Wilkie, S. Wilhelm, M. Lynch and C. Carter, Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5, Cancer Res. 66(2006), 11851-11858.
29. J.M. Llovet, Updated treatment approach to hepatocellular carcinoma, J. Gastroenterol. 40(2005), 225-235.
30. J.M. Llovet, C. Bru and J. Bruix, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin. Liver Dis. 19(1999), 329-338.
31. J.M. Llovet, A. Burroughs and J. Bruix, Hepatocellular carcinoma, Lancet 362(2003), 1907-1917.
32. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, A.C. de Oliveira, A. Santoro, J.L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T.F. Greten, P.R. Galle, J.F. Seitz, I. Borbath, D. Hãussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis and J. Bruix, SHARP Investigators Study Group. Sorafenib in advanced hepatocellularcarcinoma, N.Engl.J.Med. 4(2008), 378-390.
33. T. Matsumura, R. Makino and K. Mitamura, Frequent down- regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas, Clin.Cancer Res. 7(2001), 594-599.
34. M. Matsuo, H. Sakurai and I. Saiki, ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model, Mol. Cancer Ther. 2(2003), 557-561.
35. A. Miyoshi, Y. Kitajima, S. Kido, T. Shimonishi, S. Mat- suyama, K. Kitahara and K. Miyazaki, Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma, Br.J.Cancer 92(2005), 252-258.
36. M.A. Nieto, The snail superfamily of zinc-finger transcription factors, Nat. Rev. Mol. Cell Biol. 3(2002), 155-166.
37. No Authors listed, Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepa- tocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators, Hepatology 31(2000), 840-845.
38. R. Ogata, T. Torimura, M. Kin, T. Ueno, Y. Tateishi, R. Kuro- matsu, Y. Shimauchi, M. Sakamoto, S. Tamaki, M. Sata and K. Tanikawa, Increased expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 with tumor dedifferentiation in hepatocellular carcinomas [see comments], Hum. Pathol. 30(1999), 443-450.
39. H. Okabe, S. Satoh, T. Kato, O. Kitahara, R. Yanagawa, Y. Ya- maoka, T. Tsunoda, Y. Furukawa and Y. Nakamura, Genome- wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression, Cancer Res. 61(2001), 2129-2137.
40. K. Okuda, T. Ohtsuki, H. Obata, M. Tomimatsu, N. Okazaki, H. Hasegawa, Y. Nakajima and K. Ohnishi, Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients, Cancer 56(1985), 918-928.
41. P.A. Philip, M.R. Mahoney, C. Allmer, J. Thomas, H.C. Pitot, G. Kim, R.C. Donehower, T. Fitch, J. Picus and C. Erlichman, Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer, J. Clin. Oncol. 23(2005), 6657-6663.
42. W. Rossmanith and R. Schulte-Hermann, Biology of transforming growth factor beta in hepatocarcinogenesis, Microsc. Res. Tech. 52(2001), 430-436.
43. E. Schiffer, C. Housset, W. Cacheux, D. Wendum, C. Desbois- Mouthon, C. Rey, F. Clergue, R. Poupon, V. Barbu and O. Ros- morduc, Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis, Hepatology 41(2005), 307-314.
44. C. Schlaeger, T. Longerich, C. Schiller, P. Bewerunge, A. Mehrabi, G. Toedt, J. Kleeff, V. Ehemann, R. Eils, P. Lichter, P. Schirmacher and B. Radlwimmer, Etiology-dependent molecular mechanisms in human hepatocarcinogenesis, Hepatology 47(2) (2007), 511-520.
45. C.M. Shachaf, A.M. Kopelman, C. Arvanitis, A. Karlsson, S. Beer, S. Mandl, M.H. Bachmann, A.D. Borowsky, B. Rueb- ner, R.D. Cardiff, Q. Yang, J.M. Bishop, C.H. Contag and D.W. Felsher, MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer, Nature 431(2004), 1112-1117.
46. P.M. Siegel and J. Massague, Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer, Nat. Rev. Cancer 3(2003), 807-821.
47. K. Sugimachi, S. Tanaka, T. Kameyama, K. Taguchi, S. Aishima, M. Shimada, K. Sugimachi and M. Tsuneyoshi, Transcriptional repressor snail and progression of human hepa- tocellular carcinoma, Clin. Cancer Res. 9(2003), 2657-2664.
48. T. Terada, Y. Okada and Y. Nakanuma, Expression of im- munoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors, Hepatology 23(1996), 1341-1344.
49. J.P. Thiery, Epithelial-mesenchymal transitions in tumour progression, Nat. Rev. Cancer 2(2002), 442-454.
50. J.F. Tsai, L.Y. Chuang, J.E. Jeng, M.L. Yang, W.Y. Chang, M.Y. Hsieh, Z.Y. Lin and J.H. Tsai, Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocel- lular carcinoma, Medicine (Baltimore) 76(1997) 213-226.
51. L.M. Wakefield and A.B. Roberts, TGF-beta signaling: positive and negative effects on tumorigenesis, Curr. Opin. Genet. Dev. 12(2002), 22-29.
52. S.Y. Wang, B. Chen, Y.Q. Zhan, W.X. Xu, C.Y. Li, R.F. Yang, H. Zheng, P.B. Yue, S.H. Larsen, H.B. Sun and X. Yang, SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells, J. Hepatol. 41(2004), 267-273.
53. H. Yamamoto, F. Itoh, Y. Adachi, H. Sakamoto, M. Adachi, Y. Hinoda and K. Imai, Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepato- cellular carcinoma, Gastroenterology 112(1997), 1290-1296.
54. Q. Yu and I. Stamenkovic, Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis, Genes Dev. 14(2000), 163-176.
55. B.D. Zhu, S.J. Yuan, Q.C. Zhao, X. Li, Y. Li and Q.Y. Lu, An- titumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma, World J. Gastroenterol. 11(2005), 1382-1386.